Letrozole placebo

Phase 3

AstraZeneca

Letrozole placebo is one of 9 therapeutic programs targeting HER2-negative Breast Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

HER2-Negative Breast CancerActive, not recruiting

HER2-Negative Breast CancerPhase 3

Active, not recruiting

Competition

Competitive Landscape

9 competitors in HER2-Negative Breast Cancer

#DrugCompanyPhaseTrials

Kisqali

Novartis

Phase 3

2 2

Ibrance

Pfizer

Phase 3

1 3

Verzenio

Eli Lilly

Phase 3

1 4

Taxotere

AAvyxa

Phase 3

1 5

AZD9833

AstraZeneca

Phase 3

1 6

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 2

1 7

HB1801

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 3

1 8

Utidelone

BBeijing Biostar Pharmaceuticals Co., Ltd.

Phase 2

1 9

Letrozole placebo

AstraZeneca

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 3Active, not recruiting

HER2-Negative Breast Cancer

NCT04964934

Clinical

Trials by Indication[1]

HER2-negative Breast Cancer1 trial

A Phase III, Double-blind, Randomised Study to Assess Switching to AZD9833 (a Next Generation, Oral SERD) + CDK4/6 Inhibitor vs Continuing Aromatase Inhibitor (Letrozole or Anastrozole)+ CDK4/6 Inhibitor in HR+/HER2-MBC Patients With Detectable ESR1Mutation Without Disease Progression During 1L Treatment With Aromatase Inhibitor+ CDK4/6 Inhibitor- A ctDNA Guided Early Switch Study

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT04964934·315 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Letrozole placebo. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Letrozole placebo. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: AstraZeneca

Letrozole placebo

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

HER2-negative Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News